Correction: Cost‑effectiveness of finerenone in chronic kidney disease associated with type 2 diabetes in The Netherlands

Correction to: Cardiovascular Diabetology (2023) 22:328https://doiorg.publicaciones.saludcastillayleon.es/10.1186/s12933-023-02053-6

In the original publication of this article [1], the authors identified typographical errors in Tables 2 and 7. In Table 2, the transition probability from CKD1/2 to CKD4 should be “0.0036” instead of “0.36”. In Table 7, the total indirect costs “€111,706 and €12,4069” was incorrect and should have been “€11,706 and €12,406”, though the difference between the two values remains correct. These corrections do not affect the methodology, results, or conclusion section.

Table 2 Transition probabilities: CKD progression and first modelled CV event and OHE probabilities [13]

Table 7 Costs, QALYs, and ICER per patient over a lifetime for finerenone + SoC and SoC